Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C59H84N18O14 |
Molecular Weight | 1269.4128 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O
InChI
InChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N
InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
Molecular Formula | C59H84N18O14 |
Molecular Weight | 1269.4128 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00014Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/zoladex.html
Sources: http://www.drugbank.ca/drugs/DB00014
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/zoladex.html
Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels. Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. Goserelin is marketed under the brand names Zoladex, by AstraZeneca, or goserelin acetate.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1854 Sources: http://www.drugbank.ca/drugs/DB00014 |
|||
Target ID: CHEMBL612518 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1320049 |
0.82 nM [IC50] | ||
Target ID: CHEMBL1855 Sources: http://www.drugbank.ca/drugs/DB00014 |
1.6 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZOLADEX Approved UseZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for:
Use in combination with flutamide for the management of locally confined carcinoma of the prostate
Use as palliative treatment of advanced carcinoma of the prostate Launch Date1997 |
|||
Palliative | ZOLADEX Approved UseZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for:
Use in combination with flutamide for the management of locally confined carcinoma of the prostate
Use as palliative treatment of advanced carcinoma of the prostate Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.79 μg/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.9 μg/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
7.5 μg/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9.5 μg/L |
250 μg 1 times / day multiple, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: MULTIPLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.84 ng/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.46 ng/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
8.85 ng/mL |
10.8 mg single, subcutaneous dose: 10.8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3 ng/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36.9 μg × h/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
41.3 μg × h/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
44.5 μg × h/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
44 μg × h/L |
250 μg 1 times / day multiple, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: MULTIPLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
27.8 ng × day/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
18.5 ng × day/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.2 h |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.3 h |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
4.6 h |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5 h |
250 μg 1 times / day multiple, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: MULTIPLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73% |
10.8 mg single, subcutaneous dose: 10.8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Other AEs: Fatigue, Hot flashes... Other AEs: Fatigue (grade 2, 2 patients) Sources: Hot flashes (grade 2, 29 patients) Menses irregular (grade 2, 5 patients) Libido decreased (grade 2, 9 patients) Agitation (grade 2, 6 patients) Anxiety (grade 2, 9 patients) Depression (grade 2, 8 patients) Muscle pain (grade 2, 1 patient) Headache (grade 2, 12 patients) Sweating (grade 2, 10 patients) Thromboembolism (grade 4, 1 patient) Dryness vaginal (grade 2, 12 patients) Hot flashes (grade 3, 4 patients) Menses irregular (grade 3, 2 patients) Depression (grade 3, 1 patient) |
10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Other AEs: Gastrointestinal disorder (NOS), Bladder disorder NOS... Other AEs: Gastrointestinal disorder (NOS) (80%) Sources: Bladder disorder NOS (58%) Skin and subcutaneous conditions NEC (37%) |
10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Other AEs: Diarrhea, Cystitis... Other AEs: Diarrhea (36%) Sources: Cystitis (16%) Bleeding rectal (14%) Proctitis (8%) Hematuria (7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Muscle pain | grade 2, 1 patient | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Sweating | grade 2, 10 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Dryness vaginal | grade 2, 12 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Headache | grade 2, 12 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Fatigue | grade 2, 2 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Hot flashes | grade 2, 29 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Menses irregular | grade 2, 5 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Agitation | grade 2, 6 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Depression | grade 2, 8 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Anxiety | grade 2, 9 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Libido decreased | grade 2, 9 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Depression | grade 3, 1 patient | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Menses irregular | grade 3, 2 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Hot flashes | grade 3, 4 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Thromboembolism | grade 4, 1 patient | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Sources: |
unhealthy, 18 - 49 years Health Status: unhealthy Age Group: 18 - 49 years Sex: F Sources: |
Skin and subcutaneous conditions NEC | 37% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Bladder disorder NOS | 58% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Gastrointestinal disorder (NOS) | 80% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Bleeding rectal | 14% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Cystitis | 16% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Diarrhea | 36% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Hematuria | 7% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Proctitis | 8% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Severe toxic hepatitis during flutamide (Eulexin) treatment]. | 1989 Jan 16 |
|
Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. | 1997 |
|
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. | 2002 Sep |
|
Cirrhosis with steatohepatitis following longterm stilboestrol treatment. | 2003 Aug |
|
Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. | 2004 May |
|
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. | 2005 Jun |
Sample Use Guides
ZOLADEX (Goserelin), at a dose of 3.6 mg, should be administered subcutaneously every 28 days into the anterior abdominal wall below the navel line using an aseptic technique under the supervision of a physician
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1320049
Goserelin significantly inhibited LNCaP cell proliferation at doses between 10(-9)-10(-6) M.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:04:56 GMT 2025
by
admin
on
Wed Apr 02 07:04:56 GMT 2025
|
Record UNII |
0F65R8P09N
|
Record Status |
FAILED
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1910
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
||
|
LIVERTOX |
NBK548740
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
||
|
NDF-RT |
N0000175655
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
||
|
WHO-VATC |
QL02AE03
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
||
|
WHO-ATC |
L02AE03
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
||
|
NDF-RT |
N0000175654
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00014
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201247
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
DTXSID7048297
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
65807-02-5
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
7606
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
3879
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
1327
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
0F65R8P09N
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
SUB07962MIG
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
5311128
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
0F65R8P09N
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
D017273
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
100000084238
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
Goserelin
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
m5832
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
Z-21
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
C1374
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | |||
|
50610
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY | RxNorm | ||
|
5943
Created by
admin on Wed Apr 02 07:04:56 GMT 2025 , Edited by admin on Wed Apr 02 07:04:56 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||